Rouen Cedex

• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended
  2022-502938-30-00 5 2018-12-10 Moderate and Severe Atopic Dermatitis
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 5 2018-09-27 Moderately to Severely Active Crohn's Disease
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 5 2018-07-25 Multiple sclerosis (MS)
• A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI … Ended
  2024-515356-21-00 5 2018-04-17 Adult subject (18 years of age older) with low or intermediate-1 IPSS
• A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended
  2023-509975-17-00 4 2018-04-12 Relapsed/Refractory Follicular Lymphoma
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• ROLLOVER STUDY FOR TAZEMETOSTAT Ended
  2023-510553-41-00 9 2016-08-29 Subjects will receive tazemetostat as dictated in their antecedent stu
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W … Ended
  2023-507291-52-00 4 2014-03-24 Extranodal Marginal Zone Lymphoma
• European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatm … Ended
  2023-504282-23-00 1 Faecal incontinence
• A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, End … Ended
  2023-504643-13-00 3 Pulmonary Arterial Hypertension
• ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended
  2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
• The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab … Ended
  2024-513458-31-00 11 Dominantly Inherited Alzheimer Disease (DIAD)
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer
• Phase 2 study of inhaled SNG001 in mechanically ventilated patients with respiratory virus infection Ended
  2024-520375-27-00 4 Lower respiratory tract viral infections

Showing 457–474 of 474 trials